September 26, 2017 marked the day Stelvio joined Johnson & Johnson Innovation JLABS in San Diego, California. This vibrant ecosystem is a catalyst for innovation with a capital efficient no strings attached business model. This enables Stelvio to focus on it's mission to deliver innovative medicines of value to patients and being a resident of JLABS provides exposure to key deal makers for R&D collaborations.
https://jlabs.jnjinnovation.com/companies/featured-residents/stelvio-therapeutics
Alexey Terskikh, PhD, Chief Scientific Officer of Stelvio will be presenting in the track titled "Epigenetic Enzymes in Drug discovery" and in the session "Epigenetic Modification & Transcriptional Regulation." For more information, please visit the conference website: https://www.gtcbio.com/conferences/enzymes-drug-discovery-summit/?section=fullagenda
I'm very excited to be presenting Stelvio Oncology at Indie Bio's Demo Day on September 14, 2017. I'll be on stage presenting with eleven other great biotechnology startup companies!
Please see event details here: https://www.eventbrite.com/e/indiebio-sf-demo-day-sept-14th-2017-at-herbst-theater-tickets-35711180101
Great conversation with Pete Turner and Sandra Ponce de Leon bringing to light how we are discovering novel cancer therapeutics with our innovative technology.
http://www.poppingthebubbl.com/single-post/2017/08/18/Stelvio-Oncology-Takes-on-Cancer
We are proud to have been featured as an Emerging Company Profile in such a prestigious publication!
https://www.biocentury.com/bc-innovations/emerging-company-profile/2017-07-12/stelvio-brings-personalized-medicine-gbm-stem-
We are proud to announce that Stelvio Oncology was successfully accepted into Indie Bio Accelerator, the world's largest seed biotech accelerator.